Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$267.40
+8.7%		$260.33
$197.81
▼
$495.55
$32.93B0.311.72 million shs3.29 million shs
Biogen Inc. stock logo
BIIB
Biogen
$222.67
+3.1%		$208.99
$135.39
▼
$225.59
$31.92B0.17730,398 shs1.27 million shs
Insmed, Inc. stock logo
INSM
Insmed
$126.63
+4.2%		$114.95
$90.39
▼
$212.75
$26.54B0.822.71 million shs2.00 million shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$56.90
+1.4%		$53.48
$26.76
▼
$59.30
$8.59B1.671.99 million shs2.36 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+8.65%+11.88%+21.36%-11.94%-40.18%
Biogen Inc. stock logo
BIIB
Biogen
+3.07%+0.72%+10.33%+13.35%+59.47%
Insmed, Inc. stock logo
INSM
Insmed
+4.21%+1.80%+28.62%+20.69%-12.85%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
+1.44%+3.40%+23.24%+40.29%+91.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$267.40
+8.7%		$260.33
$197.81
▼
$495.55
$32.93B0.311.72 million shs3.29 million shs
Biogen Inc. stock logo
BIIB
Biogen
$222.67
+3.1%		$208.99
$135.39
▼
$225.59
$31.92B0.17730,398 shs1.27 million shs
Insmed, Inc. stock logo
INSM
Insmed
$126.63
+4.2%		$114.95
$90.39
▼
$212.75
$26.54B0.822.71 million shs2.00 million shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$56.90
+1.4%		$53.48
$26.76
▼
$59.30
$8.59B1.671.99 million shs2.36 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+8.65%+11.88%+21.36%-11.94%-40.18%
Biogen Inc. stock logo
BIIB
Biogen
+3.07%+0.72%+10.33%+13.35%+59.47%
Insmed, Inc. stock logo
INSM
Insmed
+4.21%+1.80%+28.62%+20.69%-12.85%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
+1.44%+3.40%+23.24%+40.29%+91.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.88
Moderate Buy$386.1444.40% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.58
Moderate Buy$227.792.30% Upside
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$205.5262.30% Upside
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.44
Hold$63.0010.72% Upside

Current Analyst Ratings Breakdown

Latest TGTX, BIIB, ALNY, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$455.00
9/1/2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$78.00
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/31/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/25/2026
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$240.00 ➝ $260.00
8/25/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$376.00
8/19/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$318.00
8/18/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
8/14/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$316.00 ➝ $256.00
8/13/2026
Biogen Inc. stock logo
BIIB
Biogen
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$300.00
(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$3.71B9.63$3.04 per share88.02$10.12 per share26.42
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.33$23.34 per share9.54$127.56 per share1.75
Insmed, Inc. stock logo
INSM
Insmed
$1.14B24.31N/AN/A$3.47 per share36.49
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$616.29M14.13$2.84 per share20.02$3.95 per share14.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$5.3849.7027.71N/A15.26%84.93%14.30%10/29/2026 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6539.4113.842.398.32%11.18%6.88%10/29/2026 (Estimated)
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$4.11N/A48.52N/A-76.94%-123.94%-44.30%10/29/2026 (Estimated)
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$447.18M$2.7420.7721.472.4055.22%73.49%34.14%11/2/2026 (Estimated)

Latest TGTX, BIIB, ALNY, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.6724-$0.06+$0.6124-$0.06$395.50 million$425.49 million
8/3/2026Q2 2026
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.3057$0.05-$0.2557$0.05$229.77 million$240.34 million
7/30/2026Q2 2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$1.63$1.84+$0.21$1.21$1.32 billion$1.29 billion
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
2.99
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
Insmed, Inc. stock logo
INSM
Insmed
0.74
3.72
3.40
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.23
4.27
3.72

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Insmed, Inc. stock logo
INSM
Insmed
N/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
8.87%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.66 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664218.38 million213.80 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
290153.07 million139.49 millionOptionable

Recent News About These Companies

Corient Private Wealth LP Purchases Shares of 39,081 TG Therapeutics, Inc. $TGTX
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-corient-private-wealth-lp-purchases-shares-of-39081-tg-therapeutics-inc-tgtx-2026-09-03/
HC Wainwright Reiterates "Buy" Rating for TG Therapeutics (NASDAQ:TGTX)
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30999707
IBD stock of the day, TG Therapeutics, eyes breakout after topping early buy point
September 2 at 5:50 PM  |  msn.comhttps://www.msn.com/en-us/news/other/ibd-stock-of-the-day-tg-therapeutics-eyes-breakout-after-topping-early-buy-point/ar-AA2bqmLM
TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?
September 2 at 12:31 PM  |  zacks.comhttps://www.zacks.com/stock/news/2983861/tg-therapeutics-tgtx-up-15-1-since-last-earnings-report-can-it-continue?cid=cs-stocknewsapi-ft-realtime_blog-2983861
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Analysts
September 2 at 4:13 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-tg-therapeutics-inc-nasdaq-tgtx-receives-consensus-rating-of-hold-from-analysts-2026-09-02/
TGTX Stock Bounces Back as Analyst Downplays Threat from Novartis
September 1 at 7:28 PM  |  profitconfidential.comP
TGTX stock pares opening losses after analyst dismisses competition from Novartis
September 1 at 7:28 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/tgtx-stock-pares-opening-losses-after-analyst-dismisses-competition-from-novartis/ar-AA2bmHU0
TG Therapeutics' (TGTX) Buy Rating Reaffirmed at HC Wainwright
September 1 at 1:23 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-tg-therapeutics-tgtx-buy-rating-reaffirmed-at-hc-wainwright-2026-09-01/
Jupiter Topco LLC Buys New Holdings in TG Therapeutics, Inc. $TGTX
September 1 at 4:55 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jupiter-topco-llc-buys-new-holdings-in-tg-therapeutics-inc-tgtx-2026-09-01/
The Manufacturers Life Insurance Company Invests $4.27 Million in TG Therapeutics, Inc. $TGTX
September 1 at 4:55 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-invests-427-million-in-tg-therapeutics-inc-tgtx-2026-09-01/
Legal & General Group Plc Invests $17.70 Million in TG Therapeutics, Inc. $TGTX
August 31 at 5:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-1770-million-in-tg-therapeutics-inc-tgtx-2026-08-31/
Man Group plc Makes New Investment in TG Therapeutics, Inc. $TGTX
August 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-man-group-plc-makes-new-investment-in-tg-therapeutics-inc-tgtx-2026-08-30/
Algert Global LLC Lowers Stock Position in TG Therapeutics, Inc. $TGTX
August 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-algert-global-llc-lowers-stock-position-in-tg-therapeutics-inc-tgtx-2026-08-29/
Bank of New York Mellon Corp Takes $49.47 Million Position in TG Therapeutics, Inc. $TGTX
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-takes-4947-million-position-in-tg-therapeutics-inc-tgtx-2026-08-28/
PDT Partners LLC Acquires Shares of 41,585 TG Therapeutics, Inc. $TGTX
August 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-pdt-partners-llc-acquires-shares-of-41585-tg-therapeutics-inc-tgtx-2026-08-27/
TG Therapeutics Tests BRIUMVI in Schizophrenia: A New Angle for Long-Term Growth
August 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/tg-therapeutics-tests-briumvi-in-schizophrenia-a-new-angle-for-long-term-growth?utm_source=marketbeat.com&utm_medium=referral
TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)
August 26, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4940308-tg-therapeutics-briumvi-peak-may-be-far-away-rating-upgrade
Castleark Management LLC Buys Shares of 150,990 TG Therapeutics, Inc. $TGTX
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-castleark-management-llc-buys-shares-of-150990-tg-therapeutics-inc-tgtx-2026-08-26/
TGTX stock outperforms 95% of stocks. Here's why.
August 24, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/tgtx-stock-outperforms-95-of-stocks-here-s-why/ar-AA2aPDus
Great Lakes Advisors LLC Invests $1.11 Million in TG Therapeutics, Inc. $TGTX
August 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-great-lakes-advisors-llc-invests-111-million-in-tg-therapeutics-inc-tgtx-2026-08-23/
235,481 Shares in TG Therapeutics, Inc. $TGTX Bought by Deutsche Bank AG
August 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-235481-shares-in-tg-therapeutics-inc-tgtx-bought-by-deutsche-bank-ag-2026-08-23/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$267.40 +21.29 (+8.65%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$265.65 -1.75 (-0.65%)
As of 04:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen stock logo

Biogen NASDAQ:BIIB

$222.67 +6.63 (+3.07%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$223.07 +0.40 (+0.18%)
As of 04:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Insmed stock logo

Insmed NASDAQ:INSM

$126.63 +5.12 (+4.21%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$126.07 -0.56 (-0.44%)
As of 04:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$56.90 +0.81 (+1.44%)
Closing price 09/2/2026 04:00 PM Eastern
Extended Trading
$56.98 +0.08 (+0.14%)
As of 04:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas